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Abstract
Background: A diagnosis of gestational diabetes (GDM) is associated with an over sevenfold increase in the risk of
developing type 2 diabetes (T2D), while among parous women with T2D, up to 30% have a history of GDM.
Lifestyle interventions have been shown to reduce the risk of incident T2D in adults with impaired glucose
tolerance, including in women with a history of GDM. The aim of this study is to establish whether a group self-
management education programme, supported by a mobile web application, can improve levels of physical activity
at 12 months in women who have had GDM.
Methods: The study is a randomised controlled trial with follow-up at 6 and 12 months. Primary outcome is
change in objectively measured average daily physical activity at 12 months. Secondary outcomes include lipid
profile, blood pressure, glycated haemoglobin, obesity, smoking and alcohol status, self-reported physical activity,
anxiety, depression and quality of life. Participants are recruited from maternity and diabetes departments in
hospital trusts in two sites in the UK. Women aged > 18 years, with a diagnosis of GDM during any pregnancy in
the previous 60 months are eligible. Participants need to have a good understanding of written and verbal English,
be able to give informed consent and have access to a smart-phone. Women who are pregnant or have type 1 or
type 2 diabetes are not eligible. In total, 290 participants will be recruited and randomly assigned, with stratification
for age and ethnicity, to either the control group, receiving usual care, or the intervention group who are invited to
participate in the Baby Steps programme. This comprises a group education programme and access to a mobile
web application which provides an education component and interacts with a wrist-worn activity monitor
providing automated messages, setting challenges and encouraging motivation.
(Continued on next page)
* Correspondence: kk22@le.ac.uk
4Diabetes Research Centre, College of Medicine, Biological Sciences and
Psychology, University of Leicester, Leicester LE5 4PW, UK
8NIHR Collaboration for Leadership in Applied Health Research and Care -
East Midlands, University of Leicester, Leicester, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sukumar et al. Trials          (2018) 19:682 
https://doi.org/10.1186/s13063-018-3067-8
(Continued from previous page)
Discussion: If effective, the Baby Steps programme could be translated into a primary care-based intervention that
women with GDM are referred to in the postnatal period. This could help them make lifestyle changes that could
reduce their future risk of T2D.
Trial registration: ISRCTN, ISRCTN17299860. Registered on 5 April 2017.
Keywords: Randomised controlled trial, Gestational diabetes, Self-management, Patient education, Diabetes
prevention
Background
Maternal outcomes following gestational diabetes
Around 700,000 women give birth in England and
Wales each year; up to 5% of them have a diagnosis of
diabetes in pregnancy [1]. Among women with diabetes
in pregnancy, gestational diabetes mellitus (GDM; de-
scribed as abnormal glucose tolerance which first de-
velops or is recognised during pregnancy) constitutes
around 85% of cases, with the remainder due to
pre-existing type 1 diabetes (T1D) or type 2 diabetes
(T2D). The aetiology of GDM is not completely known
but is due in part to the inability of the maternal pan-
creas to secrete sufficient insulin to cope with
pregnancy-induced insulin resistance in susceptible
women. The incidence of GDM is on the rise, in part
due to higher rates of obesity in the general population,
including in women of childbearing age [2–4].
Estimates suggest that lifestyle factors such as obesity,
smoking, unhealthy diet and physical inactivity may ex-
plain around 50% of the incidence of GDM [5].
A diagnosis of GDM is associated with adverse out-
comes for both the mother and her affected offspring.
These women have higher risks of pre-eclampsia,
Caesarean sections and an over sevenfold increase in the
risk of developing T2D, with the highest incidence oc-
curring within five years of the index pregnancy [6–9].
Among parous women who have a diagnosis of T2D, ≤
30% have a previous history of GDM, which means that
pregnancy and the postnatal period within the first five
years present a ‘golden opportunity’ to intervene and
alter the natural course of a disease [10, 11]. Addition-
ally, women with a history of GDM have 2–3 times
higher incidence of hypertension and ischaemic heart
disease so any intervention provided in the postnatal
period has the added potential of reducing cardiovascu-
lar disease risk [8].
Fetal macrosomia (defined as birthweight > 4–4.5 kg)
and large for gestational age (LGA) (defined as birth-
weight > 2 SD greater than mean or > 90th centile after
controlling for age and sex) are two of the most com-
mon and serious offspring outcomes of GDM in preg-
nancy. Babies born to GDM mothers are 4–7 times
likely to be macrosomic [12, 13]. Other perinatal
complications which are also associated with hypergly-
caemia during pregnancy include shoulder dystocia and
birth injuries, neonatal hypoglycaemia and respiratory
distress syndrome [14]. In the long term, offspring of
women with GDM are at increased risk of obesity,
hypertension, hyperlipidaemia and glucose intolerance
starting from childhood and early adolescence thereby
perpetuating the cycle [15–17].
Role of lifestyle interventions to reduce T2D
There is evidence from observational studies that an ac-
tive lifestyle (including increase in physical activity time
and reduction in sedentary time) is associated with
weight loss, improved glucose tolerance and lower risk
of progression to T2D in women with a history of GDM
[18, 19]. The Diabetes Prevention Programme showed,
with a randomised controlled trial (RCT) design, that in-
tensive lifestyle interventions reduced the risk of inci-
dent T2D in adults with impaired glucose tolerance
(IGT) by around 40–60% [20, 21] and, in a subgroup of
women with a history of GDM, by 53% and 35% over
three and ten years, respectively, compared to standard
care [22, 23]. Other trials have shown decreases in rates
of pre-diabetes, weight, waist circumference and lipid
levels [24–26]. Interestingly, treatment with metformin
has been shown to confer no additional benefit to life-
style interventions, presumably due to adherence issues
and less weight loss in the first year of treatment when
compared to the latter [22].
However, there are several barriers to lifestyle inter-
ventions in postpartum women with recent GDM, in-
cluding lack of time, balancing work and family
demands, and lack of childcare [27, 28]. Recently, a
web-based lifestyle intervention program in 75 women
in Boston, USA was deemed to be feasible and associ-
ated with significant weight reduction (3.3 kg below the
control group) and higher likelihood of being below
pre-pregnancy weight at 12 months postpartum [29].
The program particularly recommended gradually in-
creasing physical activity to 150 min per week, including
resistance training and making healthier dietary choices.
While most of the abovementioned trials have sug-
gested that a combination of exercise, healthy diet and
weight loss or weight maintenance protects against
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diabetes in postpartum women, there is a lack of evi-
dence about the independent effect of physical activity
in reducing progression from GDM to T2D, particularly
in high-risk populations such as minority ethnic groups.
Indeed, in observational series, increase in moderate to
vigorous physical activity, independent of body mass index
(BMI), was associated with reduction in the risk of T2D in
women after pregnancy [18]. Among non-pregnant adults,
every 2000 step per day change from baseline to 12
months is associated with an additional 8% decrease in
the cardiovascular event rate [30].
The ongoing and completed intervention programmes
for women with a history of GDM have been conducted
largely in women of white American, Australian or
European background [19, 23, 31, 32] and black,
Hispanic and mixed minority American [24, 33–35].
Therefore, there is a paucity of information about the
feasibility and effectiveness of similar programmes for
women in the UK, particularly in those of South Asian
ethnicity. It is known that up to one in five South Asian
adults globally have T2D and the diagnosis is 4–5 times
more common in South Asian adults in the UK, com-
pared to a white reference group [36, 37].
Our study will therefore be novel in developing and
testing an intervention that meets the cultural and
social needs of women in a catchment area in that
has a large multi-ethnic population (estimated to con-
stitute 25–60% of the women diagnosed with GDM
in the two research sites).
Methods/Design
Aims and objectives
1. To assess the effectiveness of a group education
programme and accompanying online web support
(Baby Steps programme) in improving objectively
measured physical activity at 12 months in
participants with a history of GDM compared to
usual care.
2. To assess the effect of the programme on other risk
factors including lipid profile, blood pressure,
resting heart rate, glycated haemoglobin (HbA1c),
obesity, smoking and alcohol status, self-reported
physical activity, anxiety, depression, quality of life,
fruit and vegetable intake compared to usual care.
3. To assess the acceptability, uptake and feasibility of
delivering the programme to women who are at
high risk of developing T2D, including those from
ethnic minority backgrounds.
Study design and setting
The study is a two-group (1:1), parallel RCT of women
who have had GDM during any pregnancy up to 60
months before the point of recruitment and are there-
fore at risk of developing T2D. Figure 1 describes the
flow of participants through the study. The RCT is being
conducted in two sites in the UK, namely University
Hospitals of Leicester NHS Trust (serving the catchment
area of Leicester City and the county of Leicestershire)
and George Eliot Hospital NHS Trust (serving the
catchment area of North Warwickshire). The protocol
was written in accordance with the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines (see Spirit Fig. 2 and the SPIRIT
Checklist, which is available as Additional file 1). The
study is sponsored by the University of Leicester and
ethical approval was granted by the East Midlands –
Derby Research Ethics Committee. The study was pro-
spectively registered (ISRCTN 17299860).
Recruitment and informed consent
Potential participants are identified from hospital da-
tabases (both maternity and diabetes departments)
and are sent a recruitment pack containing an invita-
tion letter, a brief information leaflet detailing the
study and a reply slip. Reply slips are returned to the
local study team. A member of the study team then
contacts the respondent by telephone to screen them
and arrange a baseline visit to confirm their eligibility,
take their informed consent and collect the baseline
data. Following the telephone call, they are sent a
letter confirming the details of the appointment and a
copy of the full Patient Information Leaflet (PIL).
This is sent with sufficient time to enable them to
have at least 24 h to read the PIL. A reminder invita-
tion is sent to non-responders 4–6 weeks after the
initial invitation. Potential participants who do not re-
spond to the reminder invitation within four weeks
may be called by a member of the direct care team.
The purpose of the call is not to coerce the women
to take part but to confirm they have received the in-
vitation and to find out whether they understand the
information they have been sent and whether they
have any questions. There is also the opportunity for
women to self-refer in response to posters in commu-
nity venues and publicity in the local media.
Eligibility criteria
The inclusion criteria are as follows:
 women aged ≥ 18 years, with a diagnosis of GDM
during any pregnancy resulting in delivery in the last
60 months;
 willing and able to attend the clinic and education
sessions;
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 able to speak and read English sufficiently to give
informed consent and follow the education
programme.
The exclusion criteria are as follows:
 currently pregnant;
 diagnosis of T1D or T2D;
 cancer (not in remission);
 severe diagnosed mental illness (e.g. schizophrenia,
bipolar);
 previous surgical or medical intervention to treat
obesity;
 lack of access to Internet;
 participated in another clinical intervention study in
the previous 12 weeks.
Women who consent to join the study and are identi-
fied as a result of the baseline blood tests as having
undiagnosed T2D (HbA1c > 6.4%) are withdrawn from
the study and referred back to their general practitioner.
Data collection clinics
Primary and secondary outcome data are collected at
baseline and 12 months (when participants attend data
collection clinics) and some are also collected at six
months (paperwork is sent and returned by post). Base-
line data are not collected until eligibility has been con-
firmed and the participant has given written informed
consent.
Clinics are held at the two hospital sites or at local
community venues and are staffed by appropriately
trained research nurses and healthcare assistants. All
clinical measures are carried out in accordance with
study-specific standard operating procedures (SOPs) in
place at the two sites and standard calibrated equipment
is used. Participants are given a £15 gift voucher for
every data collection clinic or education session they
Fig. 1 Consort flow diagram
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attend as a contribution towards childcare costs. If the
session is held in a venue where childcare is available,
the cost is paid by the study budget and the participant
does not receive a voucher.
Randomisation and blinding
Study identification numbers are assigned sequentially
and participants are individually randomised (1:1) strati-
fied by age (< 30 years; ≥ 30 years) and ethnicity (White
European; other) using a variable block size after their
baseline assessment. The randomisation schedule was
developed by an independent statistician and allocation
of randomisation is carried out by a researcher based in
Leicester who is independent of the team. Randomisa-
tion determines which group the participant is allocated
to (control or intervention). After randomisation,
participants in both groups are sent a letter informing
them of the outcome of the randomisation. In addition,
intervention participants are contacted by telephone to
discuss the dates available for them to attend the Baby
Steps programme. They are then sent a letter confirming
the venue and dates and times of the programme. Since
the intervention is a group self-management programme,
participants and the local research teams cannot be
blinded to the randomisation. The staff analysing the ac-
celerometer data to derive the primary outcome are
blinded to allocation.
Treatment regimens
Control group
Control group participants are sent an information
booklet about the prevention of diabetes.
Fig. 2 Schedule of enrolment, interventions and assessments as per SPIRIT 2013
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Intervention group
Participants randomised to the intervention group are
invited to participate in the Baby Steps programme. This
has two components: a group-based structured educa-
tion programme and a secure mobile web application
which provides access to information and learning tools
to supplement the group programme.
The group programme is based on Let’s Prevent
Diabetes and Walking Away from Diabetes, group
education programmes which have been shown to be ef-
fective for people at increased risk of developing T2D
[38, 39]. They are based on robust theoretical frame-
works and the philosophy is based on patient empower-
ment [40–42]. The Baby Steps programme comprises
two group sessions that are each 3 h long and are deliv-
ered approximately two weeks apart. A total of 8–10
people are booked to attend each programme and are
given the opportunity to bring a friend or member of
the family if they wish. Session 1 focuses on the back-
ground to GDM and being at risk of T2D, physical activ-
ity and other modifiable risk factors and goal setting
(Table 1). The second session revisits physical activity and
reviews progress on goals, barriers and solutions and then
covers diet and food choices with goal setting relating to
reducing risk of developing T2D. The programme is deliv-
ered in a facilitative style that encourages participation
with the use of reflective questioning and problem-solving
activities to promote engagement. The education sessions
are delivered at the two hospital sites as well as at local
community venues. The target is to attend within two
months of recruitment. However, a pragmatic approach is
taken and this is not always possible. A sensitivity analysis
will be performed to take this into account.
During Session 1, participants are given a secure link
to a mobile web application which has been developed
to accompany the programme. The application has two
main functions: first, to provide an interactive education
component to follow on from the group component;
and second, to motivate the user into becoming more
active. It contains a variety of resources of different for-
mats (e.g. video animations, expert videos, interactive ac-
tivities and quizzes) which supplement the messages
delivered during the group sessions. In addition, there
are booster sessions (released monthly for nine months)
which contain further information and challenges. Par-
ticipants are given a wrist-worn activity monitor that
can connect to the website using a human application
programming interface (API). Regular automated mes-
sages are sent in relation to goal setting, goals achieved
and the setting of new challenges with daily updates and
motivational messages. Participants can opt to join a
group who can use the website to share their challenges
and experiences with their peers. More information on
the application is provided in Additional file 2.
Development of the group education programme
followed an iterative pathway comprising various stages
of design, testing and refining the programme [43]. It
was developed by a multidisciplinary team with substan-
tial co-production from patient and public involvement
(PPI) and other stakeholder groups (including midwives
and maternity care assistants). Four meetings were held
with stakeholders (two with women who had previously
had GDM and two with healthcare professionals). The
discussions were led by an independent and experienced
qualitative researcher from the University of Leicester
and informed on content of the programme, the on-
line resource and practical issues such as the number
of sessions, ideal venues and times of the day, and
whether the session should be limited to women. The
interactive website is hosted on a safe secure server
and was developed in collaboration with a web de-
signer with healthcare professionals and patient
groups involved at all stages. An iterative pathway
similar to that used in the development of the group
programme was followed.
A small team of facilitators has been trained in each
site. They are either appropriately skilled lay people or
healthcare professionals. They attended a two-day train-
ing programme at the beginning of the study. The first
day covered the facilitator skills needed and the theories
and models underpinning the programme. The second
day covered the curriculum content and ensured they
were familiar with the teaching resources used in its de-
livery. Facilitators were given a curriculum and set of
teaching resources and delivered a ‘have a go’ session to
volunteer patients before the study started. These prac-
tice sessions were observed by a member of the training
team and feedback and further training was provided as
needed. Continued mentoring and peer support are pro-
vided to the facilitators and self-reflection and peer re-
flection after every session is encouraged.
Table 1 Contents of the Baby Steps group education
programme
Session 1 Session 2
Introduction and housekeeping (5min) Welcome back (5 min)
Your story (25 min) Sharing stories (30 min)
Blood glucose (20 min) Revisiting physical activity (15 min)
How could being at risk of diabetes
affect my health? (15 min)
Weight management (30 min)
Risk story (25 min) Food choices (45 min)
Being more active (70 min) Planning to reduce my risk
(30 min)
Reflections (5 min) Questions and future care (10 min)
TOTAL - 2 h 45min (+ 15 min
break) = 3 h
TOTAL - 2 h 45 min (+ 15min
break) = 3 h
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Outcome measures
Demographics and medical history
The participant’s age, ethnicity, smoking and alcohol status,
and number of children are recorded. Details of any relevant
history of disease and medications and first-degree family
history of diabetes are recorded. Figure 2 summarises the
outcome data which will be collected at each study visit.
Primary outcome
The primary outcome measure is change in objectively
measured physical activity from baseline to 12months
using the GENEActiv wrist-worn tri-axial accelerometer
(GENEActiv model 1.1, ActivInsights Ltd., Cambridge-
shire, UK) with a dynamic range of ± 8 g, where g is
equal to the Earth’s gravitational pull. Participants are
asked to wear the GENEActiv accelerometer on their
non-dominant wrist for eight consecutive days (24 h),
wearing the monitor from the date of the assessment
visit or from a specified date when sent in the six-month
postal follow-up. The accelerometer is initialised to col-
lect data at 100 Hz. An appropriately trained individual
instructs the participant on correct placement of the
monitor. Participants are asked to complete a log while
wearing the accelerometer to provide their waking hours
and wear time information. Participants are given a pre-
paid envelope to return the accelerometer and log book
once completed. Accelerometer data will be calibrated
and analysed according to best practice procedures
through the Lifestyle Theme of the NIHR Leicester Bio-
medical Research Centre. In brief, data will be processed
and calibrated using a bespoke open source package in R
(GGIR http://cran.r-project.org according to criteria pre-
viously described [44–46]. Data will be included if par-
ticipants have one or more valid days of data, with a
valid day defined as at least 16 h of wear time. The pri-
mary outcome is defined a priori as overall movement
intensity as quantified by the Euclidean Norm minus 1 g
(ENMO) method. In addition, time asleep, sleep quality,
time in sedentary behaviour, light-intensity physical ac-
tivity and moderate to vigorous physical activity will also
be derived using validated algorithms and thresholds.
Secondary outcomes
Clinical and anthropometric measures Blood pressure
and resting pulse rate are measured after the participant
has been sitting for 5 min. Three measurements are
made; the first measurement will be excluded when cal-
culating the mean. Body weight (kg) and height (m) are
measured and used to calculate BMI (weight in kg/m2).
Waist circumference (cm) is measured at approximately
1 cm above the iliac crest and hip circumference (cm) at
the widest area around the gluteus maximus.
Blood tests Venous blood samples for analysis of
non-fasting HbA1c and full lipid profile (total choles-
terol, LDL cholesterol, HDL cholesterol and triglycer-
ides) are collected at baseline and 12 months by trained
personnel. They are analysed in accredited laboratories
at University Hospitals of Leicester NHS Trust or at
George Eliot Hospital NHS Trust in accordance with
their SOPS and are destroyed after analysis. All labora-
tory results are reviewed and the reports signed by the
Principle Investigator at each site or an individual ap-
proved by the Chief Investigator in the Delegation of
Authority log. The results are recorded in the clinical
record form (CRF) and identified as normal, abnormal
but not clinically significant, or abnormal and clinically
significant. In case of the latter, the eligibility of the par-
ticipant to continue on the study is reviewed.
Participants may optionally consent to provide blood
samples of serum, plasma and whole blood, which will
be stored indefinitely for future ethically approved re-
search. At the end of the study, the samples from
George Eliot Hospital will be transported to University
Hospitals of Leicester using an accredited courier service
and stored in a Human Tissue Act licensed laboratory in
line with all relevant agreements in place.
Questionnaire data Participants are asked to complete
the following questionnaires at baseline, 6 and 12
months. They are given in person at the baseline and 12
months clinics and sent by post at 6 months.
1. Recent Physical Activity Questionnaire (RPAQ): the
RPAQ is designed to explore day-to-day physical ac-
tivity levels in the previous four weeks. The ques-
tionnaire comprises three sections: (1) physical
activity patterns in and around the house; (2) travel
to work and work activities; and (3) recreational ac-
tivities. RPAQ has reasonable validity for measuring
total physical activity levels [47, 48].
2. Health-Related Quality of Life EuroQoL (EQ-5D-5
L): the EQ-5D-5 L assesses health-related quality of
life and provides useful data for health economic
analyses. It is a validated measure of health status
and has five quality of life dimensions (mobility,
self-care, usual activities, pain/discomfort and
anxiety/depression) which are all coded in the range
of 1–5 [49].
3. Jenkins self-efficacy for exercise expectations
scale: this validated self-efficacy scale measures
ability to exercise when considering nine barriers.
These are weather, boredom, pain, exercising
alone, lack of enjoyment, busyness, tiredness,
stress and depression [50].
4. Hospital Anxiety and Depression Scale (HADS):
HADS is a validated scale measuring the severity of
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symptoms of anxiety and depression. It comprises
14 statements of which seven relate to anxiety and
seven relate to depression [49]. Each statement has
an option of four responses scored in the range of
0–3. Upon completion the scores selected are
totalled and reported for anxiety and depression
individually.
5. Fruit and Vegetable intake questionnaire: the Five-
A-Day Consumption and Evaluation Tool (FACET),
which is recommended by the Department of
Health, is used as a measure of fruit and vegetable
intake [51] .
Sample size
The primary outcome is based on increasing total phys-
ical activity as quantified by the Euclidean norm minus
one (ENMO) method measured in milligravity units
(mg). This is the main measure of activity derived from
the GENEActiv monitor. In order to detect a minimum
clinically significant difference of 2.1 mg, which is
equivalent to an overall increase in physical activity vol-
ume of approximately 30 min of light walking at 4 km/h,
assuming a standard deviation of 5.3 mg [52], a power of
80% and significance level of 5%, the sample size re-
quires 202 participants. To allow for 20% loss to
follow-up and 10% non-compliance of the GENEActiv
monitor, we will need to recruit 290 participants (145 in
each arm).
Statistical analysis
Descriptive characteristics at baseline will be sum-
marised by treatment arm. Numbers (with percentages)
for binary and categorical variables and means (and
standard deviations) or medians (with lower and upper
quartiles) as appropriate for continuous variables will be
presented. Preliminary graphical and tabular presenta-
tions of the data will be inspected for the correct statis-
tical modelling assumptions.
The primary analyses will use a complete case
population. For the primary outcome (change from
baseline in total physical activity), treatment arms will
be compared using linear regression with a binary in-
dicator for randomisation group as the explanatory
variable, terms for the stratification factors as con-
founders, and adjustment for the change in acceler-
ometer wear time and baseline total physical activity.
Sensitivity analyses will include a per-protocol analysis
(defined as attending at least one of the two group
education sessions, i.e. those randomised to interven-
tion but not attending either group session will be ex-
cluded) and an intention-to-treat analysis where
missing data will be imputed using multiple imputa-
tions. Interaction effects will be fitted between inter-
vention arm and age (< median vs ≥ median), and
ethnicity (White European vs other). If the interaction
term is statistically significant then stratified analyses
will be performed for that factor using the same
model as the primary analyses. Secondary outcomes
will be analysed using similar methods as the main
analysis, with an appropriate model selected depend
ent on the distribution of the outcome.
The results of all comparative analyses will be pre-
sented with 95% confidence intervals and statistical sig-
nificance for main effects will be assessed at the 5%
level. All p values shown will be two-sided. Statistical
significance for interaction effects will be assessed at the
10% level.
Qualitative interviews
A sub-sample of participants in the intervention arm
will be invited to take part in a qualitative interview
about their experience of attending the Baby Steps
programme and, in particular, of using the mobile web
application that is part of the programme. Participants
will be selected so that both those who do and those
who do not engage with the application are interviewed.
The interviews will include a discussion on whether the
programme meets the social and cultural needs of the
women. If the programme is shown to be effective in
achieving our primary and secondary outcomes, then
this qualitative information may be used to make revi-
sions to the content or mode of delivery of the
programme before it is offered to women outside a trial
setting.
Soon after attending the 12 month follow-up clinic,
selected participants will be invited to take part in a
focus group, face-to-face interview or telephone inter-
view (format will be the choice of the participant). In-
formed consent will obtained by the interviewer before
the interview starts. Interviews will be digitally re-
corded unless the participant does not consent to the
recording in which case notes will be made. Interviews
will be carried out by an experienced researcher from
the University of Leicester following an approved topic
guide and then transcribed by a transcription service
approved by the sponsor. A purposive sampling strategy
will be used to ensure that a cross-section of partici-
pants is selected (for example, women from both sites,
women who did and did not engage with the applica-
tion) and it is anticipated that about 15–20 women will
be interviewed. Interview data will be analysed through
thematic analysis where information will be put into
themes and a codebook produced, placing important
emphasis on letting the themes emerge from the empir-
ical data. This is the basis of grounded theory and thus
there will be an explicit focus on open coding and de-
velopment of themes as data is collected. Although
themes will be based on the initial topic guide, data
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collection and data analysis will be flexible in nature
and adopt a constant comparative approach. To aid
structure in analysis because transcripts and qualitative
data can be voluminous, research software packages
such as Nvivo 10 will be used.
Data management and monitoring
The Chief Investigator is responsible for ensuring that
the study is conducted in full conformity with the
current revision of the Declaration of Helsinki and with
the ICH Guidelines for Good Clinical Practice (CPMP/
ICH/135/95, July 1996). The participants’ anonymity is
maintained at all points. Participants are identified only
by an ID number and their initials on the CRF and any
electronic database. All documents and patient identifi-
able information are stored securely in locked cabinets
and on a password-protected computer or in off-site ar-
chiving rooms (according to the sponsor’s SOPs). The
study complies with the general data protection regula-
tion which requires data to be anonymised or pseudo-
anonymised as soon as it is practical to do so. All data
are entered on a validated electronic database which
only includes the participant’s ID number and is stored
for ten years and then archived according to the spon-
sor’s SOP. Any identifiable personal data will be per-
manently deleted from the servers once the final report
has been submitted or within five years if the partici-
pant has agreed to be contacted for other studies.
As this is a minimal risk study, a Data Monitoring
Committee has not been convened. Serious adverse
events (SAE) are monitored and reported in line with re-
quirements. An internal group meets every month to re-
view recruitment rate, drop out, issues concerning
delivery of the intervention and SAEs. A quarterly report
on progress is submitted to the funder.
Discussion
The National Institute for Health and Care Excellence
(NICE) guidelines on diabetes in pregnancy recom-
mend that women who have been diagnosed with
GDM are offered a fasting plasma glucose or HbA1c
test at 6–13 weeks postnatally, given lifestyle advice
(including weight control, diet and exercise) and of-
fered an annual HbA1c test [1]. It also recommends
that women with an HbA1c of 39–47 mmol/mol
(5.7% and 6.4%) are advised that they are at a high
risk of developing T2D and should be offered advice,
guidance and interventions in line with available
guidelines to prevent T2D. The American Diabetes
Association guidelines also recognises the high risk of
T2D in this group and recommends women with
GDM to have a 75 g oral glucose tolerance test
(OGTT) at 4–12 weeks postpartum followed up by
additional testing every 1–3 years if the OGTT is nor-
mal [53].
Primary care provision of postnatal care to this
group is disappointing with annual rates of long-term
follow-up of GDM in primary care only around 20%
[54]. There is a need to improve the postnatal moni-
toring of women who have had GDM as well as to
provide innovative ways to reduce progression from
GDM to T2D.
The Baby Steps programme will aim to address these is-
sues in a RCT with the primary outcome of improving
physical activity levels at 12months. The latter has been
previously shown to be independently associated with re-
duction in risk of T2D and cardiovascular events in
high-risk individuals [18, 30]. This robust programme has
been developed following a large element of PPI work
with input provided by women who have had GDM as
well as healthcare professionals who work with this pa-
tient group. It is designed to accommodate the family and
work commitments of women who have young children
and the qualitative interview component of the study will
evaluate the perception of the programme by service users
who have different levels of engagement.
An important aspect of the programme is the mobile
health technology which complements the group edu-
cation sessions and is being used increasingly in several
disciplines in medicine. Smart phones and wearable de-
vices have the potential to improve public health and
have shown some success in health behaviour change
interventions [55–57]. These new technologies could
shift the need from intensive face-to-face intervention
towards an interactive, self-directed, personalised and
cost-effective tool for women following a diagnosis of
GDM. Mobile technology has been used in the manage-
ment of GDM and the present study will add to this by
investigating whether it has a role in the prevention of
T2D in women with a history of GDM [58, 59].
The Baby Steps programme, if shown to be effective,
could be delivered in a variety of settings, including pri-
mary care, to high-risk women from multi-ethnic popu-
lations and help reduce incidence of future T2D. The
trial is restricted to women who are able to speak
English, which limits our ability to meet all the lan-
guage and cultural needs of a population with ethnic
minorities. However, our team has a good track record
of delivering similar lifestyle interventions in other lan-
guages. Therefore, if the findings from the study and
qualitative interviews are positive, it may be possible to
conduct the sessions in other languages in future to in-
crease uptake among ethnic minority populations and
target women with the highest risk of T2D.
Trial status
Recruitment started on 5 April 2017 and is ongoing.
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Protocol version
The current protocol version is Version 5; 25 May 2018.
Four substantial amendments have been approved. Amend-
ment 1 (before recruitment started) involved a change in the
randomisation procedure (from an online software system to
manual allocation using a randomisation schedule). Amend-
ment 2 involved making telephone calls to non-responders.
Amendment 3 involved a change in eligibility criteria (from
recruited within 36months of most recent delivery to re-
cruited within 60months of any delivery). Amendment 4 in-
volved carrying out qualitative interviews with participants
from the intervention arm.
Additional files
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 120 kb)
Additional file 2: Baby Steps Mobile Web Application. (PDF 327 kb)
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